Claims for Patent: 9,925,310

Summary for Patent: 9,925,310

Title:	Biocompatible and bioabsorbable derivatized chitosan compositions
Abstract:	The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.
Inventor(s):	McGrath; Barbara (Portland, OR), McCarthy; Simon (Portland, OR), Kuhn; Sam (Portland, OR), Wold; Alysha (Portland, OR), Stolten; Michael (Portland, OR), Bennett; Amanda (Portland, OR)
Assignee:	Tricol Biomedical, Inc. (Portland, OR)
Application Number:	15/371,010
Patent Claims:	1. A biocompatible, bioabsorbable deacetylated and reacetylated chitosan composition comprising a reacetylated chitosan having a molecular weight of about 90 kDa to about 170 kDa and a degree of N-deacetylation of between about 15% and 40%. 2. The composition of claim 1, wherein the composition is initially soluble in an aqueous solution below or at about pH 6.5. 3. The composition of claim 1, further comprising at least one of an acid content between about 0% (w/w) and 8% (w/w) and an active ingredient selected from the group consisting of calcium, albumin, fibrinogen, thrombin, factor VIIa, factor XIII, thromboxane A2, prostaglandin-2a, activated Protein C, vitronectin, chrondroitin sulfate, heparan sulfate, keratan sulfate, glucosamine, heparin, decorin, biglycan, testican, fibromodulin, lumican, versican, neurocan, aggrecan, perlecan, lysozyme, lysly oxidase, hexose oxidase, cholesterol oxidase, pyranose oxidase, choline oxidase, pyruvate oxidase, glycollate oxidase and/or aminoacid oxidase, hexose, cholesterol, pyranose, choline, pyruvate, glycollate, aminoacid, epidermal growth factor, platelet derived growth factor, Von Willebrand factor, tumor necrosis factor (TNF), transforming growth factor (TGF), insulin like growth factor, fibroblast growth factor (FGF), keratinocyte growth factor, vascular endothelial growth factor (VEGF), nerve growth factor, bone morphogenic protein (BMP), hepatoma derived growth factor (HDGF), interleukin, amphiregulin, retinoic acid, erythropoietin, mafenide acetate, silver sulfadiazine, silver nitrate, nanocrystalline silver, penicillin, ampicillin, methicillin, amoxicillin, clavamox, clavulanic acid, aztreonam, imipenem, streptomycin, kanamycin, tobramycin, gentamicin, vancomycin, clindamycin, lincomycin, erythromycin, polymyxin, bacitracin, amphotericin, nystatin, rifampicin, tetracycline, doxycycline, chloramphenicol, cefuroxime, cefradine, flucloxacillin, floxacillin, dicloxacillin, potassium clavulanate, clotrimazole, cyclopiroxalomine, terbidifine, ketoconazole, paclitaxel, docetaxel, imatinib, exemestane, tamoxifen, vemurafenib, ipilimumab, dacarbazine, interleukin-2, abiraterone, doxorubicin, 5-fluorouracil, tamoxifen, octreotide, sorafenib, resveratrol, ketamine, diclofenac, ibuprofen, paracetamol, codeine, oxycodone, hydrocodone, dihydromorphine, pethidine, buprenorphine, tramadol, venlafaxine, flupirtine, carbamazepine, gabapentin, pregabalin, lidocaine, autologous cell lines, stem cells, and combinations thereof. 4. The composition of claim 1, wherein the composition is cross-linked with at least one of gelatin and collagen. 5. The composition of claim 1, wherein the composition is capable of in vivo bioabsorption in less than one of about 90 days, about 60 days, about 30 days, and about 14 days. 6. The composition of claim 5, wherein the composition is at least 85% absorbed. 7. The composition of claim 1, wherein the composition has a degree of N-deacetylation between about 15% to 35%. 8. The composition of claim 1, wherein the composition comprises one of a freeze-dried sponge, a freeze-dried foam, a non-freeze-dried foam, an implant, a tissue scaffold, an implant device surface coating, a matrix, a fiber, a powder, a sheet, a film, a membrane, a nanofiber, a nanoparticle, and a hydrogel. 9. A method of making a biocompatible, bioabsorbable chitosan composition comprising: obtaining deacetylated chitosan; producing reacetylated chitosan from the deacetylated chitosan having a degree of N-deacetylation of between 15% and 30%; and resolubilizing the reacetylated chitosan to aqueous solution using carbonic acid. 10. The method of claim 9, further comprising selecting a deacetylated chitosan starting material having at least one of a degree of N-deacetylation of between about 75% to 100% and a purity of at least 99%. 11. The method of claim 9, further comprising reducing chitosan free amine functionality of a glucosamine C-2 nitrogen of the deacetylated chitosan with an electrophile. 12. The method of claim 9, further comprising combining the resolubilized reacetylated chitosan aqueous acidic solution and an aqueous gelatin solution. 13. The method of claim 9, further comprising cross-linking the chitosan with at least one of gelatin and collagen. 14. The method of claim 13, further comprising using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride to accomplish the cross-linking. 15. The method of claim 9, further comprising processing the chitosan into at least one of a freeze-dried sponge, a freeze-dried foam, a non-freeze-dried foam, an implant, a tissue scaffold, an implant device surface coating, a matrix, a fiber, a powder, a sheet, a film, a membrane, a nanofiber, a nanoparticle, and a hydrogel. 16. The composition of claim 1, wherein the composition has a degree of N-deacetylation between about 20% to 35%. 17. The composition of claim 1, wherein the composition has a degree of N-deacetylation between about 20% to 30%. 18. A biocompatible, bioabsorbable deacetylated and reacetylated chitosan composition comprising a reacetylated chitosan having a degree of N-deacetylation of between 15% and 30% and cross-linked with at least one of gelatin and collagen. 19. The composition of claim 1, further comprising an acid content between about 2% (w/w) and 8% (w/w). 20. The composition of claim 18, further comprising an acid content between about 2% (w/w) and 8% (w/w).

Details for Patent 9,925,310

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2033-03-14